The MHRA GCP inspection guidance now anchors the UK’s biggest clinical trials overhaul in two decades. Updated on 22 September 2026, it brings together ICH E6(R3) principles, tighter trial master file rules, and a refreshed inspection dossier in one reference for sponsors.
What the MHRA GCP Inspection Guidance Now Covers
The UK Medicines and Healthcare products Regulatory Agency (MHRA) last updated its guidance on Good Clinical Practice (GCP) inspections on 22 September 2026.
It reflects the framework that took effect under the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 on 28 April 2026.
The latest change reworded the dossier submission rules and introduced a dedicated dossier for organisations providing computerised systems to clinical trials.
The guidance sets out how routine risk-based and triggered inspections run, how findings are graded, and how escalation works.
It is the MHRA’s central reference for sponsors, contract research organisations, universities, and NHS sites preparing for an inspection.
Compliance with the principles of the International Council for Harmonisation (ICH) E6(R3) guideline is now a legal requirement for every clinical trial of an investigational medicinal product in the UK.
Sponsors and investigators must also give due regard to Annex 1, which covers interventional trials, and Annex 2, which covers non-traditional designs. Inspectors assess both proportionately to risk.
The UK-specific annotations specify which UK regulatory requirements and guidance apply wherever the guideline refers to applicable regulatory requirements, so sponsors need not guess.
Tighter Rules on the Trial Master File and Inspection Dossier
Organisations notified that they are being considered for inspection must submit a GCP inspection dossier and a clinical trials spreadsheet within 30 days, using the MHRA’s current templates.
The trial master file (TMF) remains central to the process. The complete TMF is the basis for inspection, and inspectors expect direct access to every electronic system that forms part of it.
- Organisation charts, standard operating procedure lists, and facility overviews, submitted with the dossier
- Direct, working access to each electronic TMF (eTMF) system, including records held by any subcontracted service provider
- A completed clinical trials spreadsheet on the MHRA template
Grading, Escalation, and the Cost of Non-Compliance
Findings fall into three tiers: Critical, major, and other.
A critical finding reflects significant, unjustified departures from legislative requirements that put participant safety or data reliability at risk. A TMF that inspectors cannot readily access is also critical.
Major findings include a number of departures within a single area of responsibility, which points to a systematic quality assurance failure.
Critical findings are referred to the cross-agency GCP Inspection Action Group, which may consider early re-inspection, referral to bodies such as the Health Research Authority or the General Medical Council, suspension of a trial authorisation, or an infringement notice.
Every organisation must respond to the inspection report with a corrective and preventive action (CAPA) plan. The MHRA issues a formal GCP inspection statement once responses are adequate.
Preparing for the Next MHRA GCP Inspection
Preparation for GCP inspection now starts long before a notification letter arrives.
Decision-makers should confirm that every trial started before 28 April 2026 has a documented ICH E6(R3) impact assessment, identify which systems form the TMF, and rehearse dossier assembly against the latest checklist.
- Audit trial master files for direct electronic access across every subcontracted vendor
- Refresh GCP training in a risk-based order, prioritising higher-risk trials first
- Assign clear ownership for corrective and preventive action responses ahead of any finding
Updated GCP inspection guidance underpins the UK’s regulatory reset for every sponsor, contract research organisation, and NHS site running trials.
Any Clinical Development professional who treats it as a checklist exercise risks missing the bigger shift toward proportionate, risk-based oversight.
At Pharmatica, we track the systems, standards, and enforcement patterns shaping pharmaceutical regulation, connecting today’s guidance changes to tomorrow’s inspection outcomes. Explore our Regulatory Insights for more analysis on the rules reshaping UK clinical trials.
Pharmatica: Insight. Connection. Impact.
Comments (0)